Comparative Pharmacology
Head-to-head clinical analysis: ACETAMINOPHEN AND IBUPROFEN versus TOLECTIN 600.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACETAMINOPHEN AND IBUPROFEN versus TOLECTIN 600.
ACETAMINOPHEN AND IBUPROFEN vs TOLECTIN 600
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetaminophen is a centrally acting analgesic and antipyretic whose exact mechanism is not fully understood, but is thought to involve inhibition of cyclooxygenase (COX) in the brain and modulation of cannabinoid receptors. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2, reducing prostaglandin synthesis.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
Oral: Acetaminophen 325 mg and ibuprofen 200 mg, 1-2 tablets every 6 hours as needed, not exceeding 6 tablets/24 hours.
600 mg orally three times daily; maximum 1800 mg/day.
None Documented
None Documented
Acetaminophen: 2-3 hours (normal hepatic function). Ibuprofen: 2-4 hours (immediate-release); prolonged in overdose or hepatic impairment.
Terminal elimination half-life is approximately 5 hours (range 4-6 hours) in healthy adults; prolonged in renal impairment.
Acetaminophen: renal excretion of metabolites (glucuronide 55%, sulfate 30%, cysteine/mercapturate <10%); <5% unchanged. Ibuprofen: renal excretion of metabolites (conjugates) 90%; <10% unchanged; minor biliary/fecal.
Renal: approximately 90% as metabolites and conjugates; biliary/fecal: minor (less than 10%)
Category D/X
Category C
NSAID
NSAID